NCT05038631 2025-12-02
Managed Access Programs for LEE011, Ribociclib
Novartis
Available
Clinical Trials
13 trialsNCT05974410 2025-10-02
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
AVM Biotechnology Inc
Available
NCT04100694 2025-05-20
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Merus B.V.
Approved for marketing
NCT03906331 2025-01-17
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Eli Lilly and Company
Approved for marketing
NCT03763604 2024-12-16
Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer
Eli Lilly and Company
Approved for marketing
NCT05108740 2021-12-09
MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer
Novartis
No longer available
NCT03706573 2021-07-19
Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer
Novartis
No longer available
NCT03554434 2020-03-02
An Expanded Access Program for AM0010 (Pegilodecakin)
Eli Lilly and Company
No longer available
NCT03424473 2020-02-25
Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer
Seagen Inc.
No longer available
NCT02792725 2017-10-31
Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer
Eli Lilly and Company
Approved for marketing
NCT01120561 2017-02-15
A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer
Genentech, Inc.
No longer available
NCT01240421 2015-05-22
An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory
Eisai Inc.
Approved for marketing
NCT01130259 2013-09-17
An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer
Sanofi
No longer available